Skip to main content
Novo Nordisk takes on Lilly with newly approved diabetes drug

Novo Nordisk's newly approved Ozempic will compete directly with Eli Lilly and Co.'s Trulicity in the diabetes drug market. The new drug will be priced at about $676 per prescription, which the company said is on par with other drugs in the class.

Full Story: